share_log

Royce & Associates LP Has $45.57 Million Position in Enovis Co. (NYSE:ENOV)

Royce & Associates LP Has $45.57 Million Position in Enovis Co. (NYSE:ENOV)

Royce & Associates LP 在 Enovis Co.拥有4,557万美元的头寸(纽约证券交易所代码:ENOV)
Financial News Live ·  2023/01/19 09:21

Royce & Associates LP lifted its holdings in Enovis Co. (NYSE:ENOV – Get Rating) by 58.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 989,227 shares of the company's stock after purchasing an additional 363,928 shares during the period. Royce & Associates LP owned 1.83% of Enovis worth $45,574,000 at the end of the most recent reporting period.

Royce&Associates LP在最近提交给美国证券交易委员会(Securities And Exchange Commission)的13F文件中称,该公司第三季度将其在Enovis Co.(NYSE:ENOV-GET评级)的持股比例提高了58.2%。该基金在此期间额外购买了363,928股后,持有该公司989,227股股票。在最近一次报告期结束时,Royce&Associates LP拥有Enovis 1.83%的股份,价值45,574,000美元。

Several other institutional investors and hedge funds have also modified their holdings of the business. Price T Rowe Associates Inc. MD acquired a new stake in shares of Enovis in the 2nd quarter valued at $333,199,000. Cooke & Bieler LP acquired a new position in Enovis during the 2nd quarter worth $86,274,000. State Street Corp acquired a new position in Enovis during the 2nd quarter worth $72,935,000. Eminence Capital LP acquired a new position in Enovis during the 2nd quarter worth $66,263,000. Finally, Millennium Management LLC acquired a new position in Enovis during the 2nd quarter worth $52,132,000. Institutional investors and hedge funds own 96.73% of the company's stock.

其他几家机构投资者和对冲基金也调整了对该公司的持股。Price T Rowe Associates Inc.MD在第二季度收购了价值333,199,000美元的Enovis股票。Cooke&Bieler LP在第二季度收购了Enovis的一个新头寸,价值86,274,000美元。道富银行在第二季度收购了Enovis的一个新头寸,价值72,935,000美元。卓越资本有限公司在第二季度收购了Enovis的一个新头寸,价值66,263,000美元。最后,Millennium Management LLC在第二季度收购了Enovis的一个新头寸,价值52,132,000美元。机构投资者和对冲基金持有该公司96.73%的股票。

Get
到达
Enovis
伊诺维斯
alerts:
警报:

Insider Buying and Selling at Enovis

Enovis的内幕买卖

In other Enovis news, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total value of $75,567.76. Following the transaction, the chief financial officer now directly owns 44,605 shares in the company, valued at $2,465,764.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Daniel A. Pryor sold 67,421 shares of the company's stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $54.58, for a total transaction of $3,679,838.18. Following the transaction, the executive vice president now directly owns 75,731 shares in the company, valued at $4,133,397.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher M. Hix sold 1,367 shares of the company's stock in a transaction that occurred on Wednesday, December 14th. The stock was sold at an average price of $55.28, for a total transaction of $75,567.76. Following the transaction, the chief financial officer now owns 44,605 shares in the company, valued at $2,465,764.40. The disclosure for this sale can be found here. Company insiders own 8.30% of the company's stock.

在Enovis的其他消息中,首席财务官Christopher M.Hix在12月14日星期三的交易中出售了1,367股Enovis股票。这些股票的平均价格为55.28美元,总价值为75,567.76美元。交易完成后,这位首席财务官现在直接持有该公司44,605股股票,价值2,465,764.40美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节。在其他新闻方面,执行副总裁Daniel·普赖尔在11月15日星期二的一笔交易中出售了67,421股该公司股票。这些股票的平均价格为54.58美元,总成交金额为3,679,838.18美元。交易完成后,执行副总裁总裁现在直接持有该公司75,731股股份,价值4133,397.98美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站。此外,首席财务官克里斯托弗·M·希克斯在12月14日(星期三)的一次交易中出售了1,367股公司股票。该股以55.28美元的平均价格出售,总成交金额为75567.76美元。交易完成后,这位首席财务官现在拥有该公司44,605股股票,价值2,465,764.40美元。关于这次销售的披露可以找到这里。公司内部人士持有该公司8.30%的股份。

Wall Street Analysts Forecast Growth

华尔街分析师预测经济增长

ENOV has been the subject of a number of research analyst reports. Wells Fargo & Company cut their target price on shares of Enovis from $60.00 to $53.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 26th. Robert W. Baird dropped their price objective on shares of Enovis from $73.00 to $68.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Evercore ISI boosted their price objective on shares of Enovis to $68.00 in a report on Tuesday, January 3rd. TheStreet downgraded shares of Enovis from a "c" rating to a "d" rating in a report on Wednesday, November 2nd. Finally, Jefferies Financial Group initiated coverage on shares of Enovis in a report on Wednesday, October 12th. They set a "buy" rating and a $60.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Enovis has an average rating of "Moderate Buy" and an average price target of $63.50.
ENOV一直是许多研究分析师报告的主题。10月26日,富国银行在一份研究报告中将Enovis股票的目标价从60.00美元下调至53.00美元,并为该公司设定了“同等权重”的评级。罗伯特·W·贝尔德在11月3日星期四的一份报告中将Enovis的股票目标价从73.00美元下调至68.00美元,并对该股设定了“跑赢大盘”的评级。Evercore ISI在1月3日周二的一份报告中将Enovis的股价目标上调至68.00美元。华尔街在11月2日星期三的一份报告中将Enovis的股票评级从C级下调至D级。最后,杰富瑞金融集团在10月12日星期三的一份报告中启动了对Enovis股票的报道。他们为该股设定了“买入”评级和60.00美元的目标价。两名股票研究分析师对该股的评级为持有,七名分析师对该公司股票的评级为买入。根据MarketBeat的数据,Enovis的平均评级为“中等买入”,平均目标价为63.50美元。

Enovis Stock Up 0.8 %

Enovis股价上涨0.8%

NYSE ENOV opened at $58.37 on Thursday. The stock has a market cap of $3.16 billion, a P/E ratio of 121.61 and a beta of 1.99. The company's 50-day simple moving average is $55.14 and its 200 day simple moving average is $53.34. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $134.43.

纽约证交所ENOV周四开盘报58.37美元。该股市值为31.6亿美元,市盈率为121.61,贝塔系数为1.99%。该公司的50日简单移动均线切入位在55.14美元,200日简单移动均线切入位在53.34美元。Enovis Co.股价跌至43.88美元的12个月低点,以及134.43美元的12个月高点。

Enovis (NYSE:ENOV – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.12. The firm had revenue of $383.81 million for the quarter, compared to analyst estimates of $379.75 million. Enovis had a net margin of 0.94% and a return on equity of 4.46%. Research analysts anticipate that Enovis Co. will post 2.24 earnings per share for the current year.

Enovis(纽约证券交易所代码:ENOV-GET Rating)最近一次发布季度收益报告是在11月2日星期三。该公司公布本季度每股收益为0.59美元,比分析师普遍预期的0.47美元高出0.12美元。该公司本季度营收为3.8381亿美元,而分析师预期为3.7975亿美元。Enovis的净利润率为0.94%,股本回报率为4.46%。研究分析师预计,Enovis Co.本年度每股收益将达到2.24欧元。

About Enovis

关于Enovis

(Get Rating)

(获取评级)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Enovis公司是一家全球性的医疗技术公司。该公司开发、制造和分销医疗器械产品,供整形外科专家、外科医生、初级保健医生、疼痛管理专家、物理治疗师、足科医生、脊椎按摩师、运动训练师和其他医疗保健专业人员使用,以治疗因退行性疾病、畸形、创伤事件和运动相关伤害而导致的肌肉骨骼疾病患者。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Enovis (ENOV)
  • Procter & Gamble Earnings: A Gamble Worth Taking
  • Stocks Slide, Economic Report Paints Gloomy Picture For Economy
  • What does Nu Holdings Stock Have To Do With Warren Buffett?
  • J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
  • Is Intel Stock On The Verge Of Breaking Out?
  • 免费获取StockNews.com关于Enovis的研究报告(ENOV)
  • 宝洁收益:一场值得冒险的赌博
  • 股市下滑,经济报告为经济描绘黯淡图景
  • 如新控股股票与沃伦·巴菲特有什么关系?
  • J.B.亨特买房,物流公司成为焦点
  • 英特尔股票是否即将突破?

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Enovis Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Enovis和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发